Compare Stocks: GMAB, REGN, MRNA, and ARGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$923.49 -1.3%	$959.00	$661.85 ▼ $1,072.75	$57.74B	0.45	332,893 shs	76,924 shs
GMAB Genmab A/S	$34.22 -1.0%	$32.65	$23.62 ▼ $35.90	$21.34B	0.81	2.02 million shs	469,317 shs
MRNA Moderna	$187.25 -0.9%	$122.75	$22.28 ▼ $208.90	$74.60B	1.09	11.89 million shs	2.48 million shs
REGN Regeneron Pharmaceuticals	$736.29 +0.2%	$786.71	$541.00 ▼ $859.34	$75.69B	0.16	827,728 shs	65,256 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.39%	-2.72%	-8.99%	-0.39%	+21.98%
GMAB Genmab A/S	-3.14%	-0.80%	+3.78%	+21.19%	+8.75%
MRNA Moderna	-1.89%	-3.02%	+22.47%	+136.89%	+584.57%
REGN Regeneron Pharmaceuticals	-3.09%	-7.69%	-10.80%	+12.31%	+22.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$923.49 -1.3%	$959.00	$661.85 ▼ $1,072.75	$57.74B	0.45	332,893 shs	76,924 shs
GMAB Genmab A/S	$34.22 -1.0%	$32.65	$23.62 ▼ $35.90	$21.34B	0.81	2.02 million shs	469,317 shs
MRNA Moderna	$187.25 -0.9%	$122.75	$22.28 ▼ $208.90	$74.60B	1.09	11.89 million shs	2.48 million shs
REGN Regeneron Pharmaceuticals	$736.29 +0.2%	$786.71	$541.00 ▼ $859.34	$75.69B	0.16	827,728 shs	65,256 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.39%	-2.72%	-8.99%	-0.39%	+21.98%
GMAB Genmab A/S	-3.14%	-0.80%	+3.78%	+21.19%	+8.75%
MRNA Moderna	-1.89%	-3.02%	+22.47%	+136.89%	+584.57%
REGN Regeneron Pharmaceuticals	-3.09%	-7.69%	-10.80%	+12.31%	+22.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.88	Moderate Buy	$1,158.61	25.46% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	15.45% Upside
MRNA Moderna	2.08	Hold	$77.83	-58.43% Downside
REGN Regeneron Pharmaceuticals	2.69	Moderate Buy	$809.50	9.94% Upside

Current Analyst Ratings Breakdown

Latest GMAB, REGN, MRNA, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	REGN Regeneron Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$870.00 ➝ $930.00
10/1/2026	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$850.00
9/30/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$60.00 ➝ $80.00
9/29/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$737.00
9/28/2026	REGN Regeneron Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/25/2026	MRNA Moderna	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/23/2026	MRNA Moderna	Singular Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/21/2026	REGN Regeneron Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/14/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/10/2026	REGN Regeneron Pharmaceuticals	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$800.00 ➝ $920.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	13.60	$20.54 per share	44.95	$118.34 per share	7.80
GMAB Genmab A/S	$3.72B	5.74	$1.54 per share	22.16	$9.10 per share	3.76
MRNA Moderna	$1.94B	38.46	N/A	N/A	$22.14 per share	8.46
REGN Regeneron Pharmaceuticals	$14.34B	5.29	$40.77 per share	18.06	$295.66 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	35.45	24.78	0.99	32.19%	43.59%	36.66%	N/A
GMAB Genmab A/S	$963M	$1.27	26.92	21.79	1.94	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	18.17	14.57	1.49	27.86%	13.47%	10.34%	10/30/2026 (Estimated)

Latest GMAB, REGN, MRNA, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$15.99	N/A	N/A	N/A	$4.54 billion	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.51%	N/A	9.29%	N/A

Latest GMAB, REGN, MRNA, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
GMAB Genmab A/S	0.81	2.46	2.44
MRNA Moderna	0.09	2.29	2.18
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GMAB Genmab A/S	7.07%
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GMAB Genmab A/S	1.54%
MRNA Moderna	10.80%
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable

GMAB, REGN, MRNA, and ARGX Headlines

Recent News About These Companies

Regeneron reports 73% response rate for ubamatamab in ovarian cancer

October 1 at 5:32 PM | streetinsider.com

Regeneron's Ubamatamab, Trevogrumab Show Strong Results In Cancer And Obesity Studies

October 1 at 5:32 PM | rttnews.com

Regeneron drops after early-stage trial data for ovarian cancer therapy

October 1 at 5:32 PM | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript

October 1 at 4:00 PM | seekingalpha.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00

October 1 at 2:47 PM | marketbeat.com

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

October 1 at 12:30 PM | finance.yahoo.com

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

October 1 at 12:30 PM | finance.yahoo.com

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

October 1 at 11:35 AM | globenewswire.com

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

October 1 at 11:30 AM | globenewswire.com

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

October 1 at 11:01 AM | marketbeat.com

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

October 1 at 10:50 AM | zacks.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus

October 1 at 8:41 AM | marketbeat.com

Regeneron and Sanofi expand alliance with $1 Bln upfront deal

October 1 at 7:30 AM | streetinsider.com

Sanofi gains after expanding Regeneron partnership with $8 billion deal

October 1 at 7:30 AM | finance.yahoo.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Sector Perform Rating from Royal Bank Of Canada

October 1 at 2:32 AM | americanbankingnews.com

Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

October 1 at 2:27 AM | wsj.com

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

October 1 at 1:37 AM | finance.yahoo.com

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

October 1 at 1:37 AM | finance.yahoo.com

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

October 1 at 1:00 AM | globenewswire.com

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

October 1 at 1:00 AM | globenewswire.com

Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial

September 30 at 6:04 PM | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GMAB, REGN, MRNA, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$923.49 -12.51 (-1.34%)

As of 10:27 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Genmab A/S NASDAQ:GMAB

$34.22 -0.34 (-0.97%)

As of 10:27 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Moderna NASDAQ:MRNA

$187.25 -1.69 (-0.89%)

As of 10:27 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$736.29 +1.48 (+0.20%)

As of 10:27 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GMAB, REGN, MRNA, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GMAB, REGN, MRNA, and ARGX Earnings

Compare Dividends

Latest GMAB, REGN, MRNA, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GMAB, REGN, MRNA, and ARGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GMAB, REGN, MRNA, and ARGX Company Descriptions

argenex NASDAQ:ARGX

Genmab A/S NASDAQ:GMAB

Moderna NASDAQ:MRNA

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools